Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224672 | 0.84 | ACHE (0.50) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL21017211 | 0.77 | ACHE (0.74) | ACHERUNX1LTA4HNPC1 | |
| SCHEMBL14224673 | 0.75 | PDGFRB (0.45) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL3383838 | 0.75 | FGFR1 (0.87) | ACHEPDGFRBFGFR1KDRLTA4H | |
| SCHEMBL19228811 | 0.74 | ACHE (0.66) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL5952294 | 0.74 | FGFR1 (0.65) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL17525972 | 0.74 | RUNX1 (0.86) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL21018063 | 0.74 | ACHE (0.82) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL3382470 | 0.74 | KDR (0.60) | ACHEPDGFRBFGFR1KDRRUNX1 | |
| SCHEMBL13373318 | 0.73 | KDM4E (0.56) | ACHEPDGFRBFGFR1LTA4HMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | ACHE 634/4885PDGFRB 3401/4885FGFR1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.